MedTrace Logo

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

NCT06870617 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-10-03

No results posted yet for this study

Summary

The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PGA) is designed to improve clinical usability and adoption, but its implementation in real-world settings has not been evaluated. The PACE-70 study aims to evaluate PGA implementation and resultant chemotherapy dose modification among older adults with advanced cancer treated in a community setting. An exploratory aim will evaluate how the PGA, body composition (via abdominal computed tomography scan) and step count monitoring (via FitBit) correlate with chemotherapy toxicity and other clinical outcomes.

Conditions

Interventions

OTHER

Practical Geriatric Assessment

The PGA will be administered via the electronic health record (EHR), available for patients to complete independently prior to an initial medical oncology visit, or during the visit with staff assistance. Results from the PGA will be shared automatically with clinical teams via the EHR, including a Best Practice Alert highlighting any identified geriatric impairment(s) and ASCO's recommendation for PGA-adapted care.

OTHER

Correlation of body composition PGA and step count with outcomes

Monitoring of step counts (measured via FitBit) and body composition (measured via standard abdominal CT scans)

Sponsors & Collaborators

Principal Investigators

  • Ramy Sedhom, M.D. · Penn Princeton

  • Samuel Takvorian, M.D. · Abramson Cancer Center

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-07-01
Completion
2026-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06870617 on ClinicalTrials.gov